People are different and so is their cancer, patients should be treated individually.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
IGNITE update – Eight hospitals have been enrolled in the program
Please click here to download our Memorandum
Please click here to download our Teaser
Interim Report Q1 2022 released
View previous reports
Annual General Meeting
Watch past presentations
Interim Report Q2 2022 released
Interim Report Q3 2022 released
IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.